$LPTX
LEAP THERAPEUTICS, INC.

2022 Q4 Form 10-Q Financial Statement

#000110465922117613 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $375.0K
YoY Change -100.0% -100.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.909M $3.186M $2.438M
YoY Change 4.15% 30.68% -2.87%
% of Gross Profit
Research & Development $11.03M $12.10M $10.08M
YoY Change 36.73% 20.1% 87.69%
% of Gross Profit
Depreciation & Amortization $4.000K $4.000K $7.000K
YoY Change -50.0% -42.86% -30.0%
% of Gross Profit
Operating Expenses $13.94M $15.29M $12.52M
YoY Change 28.35% 22.16% 58.76%
Operating Profit -$15.29M -$12.14M
YoY Change 25.93% 61.69%
Interest Expense $1.213M $11.00K $9.000K
YoY Change 3467.65% 22.22% -47.06%
% of Operating Profit
Other Income/Expense, Net $775.0K $652.0K $1.269M
YoY Change -316.48% -48.62% 451.74%
Pretax Income -$11.96M -$15.09M -$11.14M
YoY Change 10.57% 35.51% 57.84%
Income Tax $147.0K
% Of Pretax Income
Net Earnings -$12.10M -$15.09M -$11.14M
YoY Change 12.18% 35.51% 57.84%
Net Earnings / Revenue -2970.4%
Basic Earnings Per Share -$0.13 -$0.14
Diluted Earnings Per Share -$0.11 -$0.13 -$142.4K
COMMON SHARES
Basic Shares Outstanding 99.02M 99.02M 59.67M
Diluted Shares Outstanding 113.2M 78.22M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.50M $78.31M $124.8M
YoY Change -43.0% -37.24% 115.2%
Cash & Equivalents $65.50M $78.31M $124.8M
Short-Term Investments
Other Short-Term Assets $351.0K $374.0K $271.0K
YoY Change -54.36% 38.01% 23.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $67.95M $79.94M $125.1M
YoY Change -41.86% -36.1% 114.21%
LONG-TERM ASSETS
Property, Plant & Equipment $20.00K $24.00K $43.00K
YoY Change -44.44% -44.19% -93.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $45.00K $1.117M
YoY Change -66.67% -95.97% -22.97%
Total Long-Term Assets $2.403M $2.227M $2.979M
YoY Change 131.73% -25.24% 39.21%
TOTAL ASSETS
Total Short-Term Assets $67.95M $79.94M $125.1M
Total Long-Term Assets $2.403M $2.227M $2.979M
Total Assets $70.35M $82.17M $128.1M
YoY Change -40.33% -35.85% 111.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.657M $6.276M $7.966M
YoY Change 35.04% -21.22% 212.39%
Accrued Expenses $5.152M $5.042M $2.597M
YoY Change -3.99% 94.15% -2.73%
Deferred Revenue $375.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.23M $11.72M $11.26M
YoY Change 12.4% 4.1% 67.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $262.0K $369.0K $0.00
YoY Change 608.11% -100.0%
Total Long-Term Liabilities $262.0K $369.0K $0.00
YoY Change 608.11% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.23M $11.72M $11.26M
Total Long-Term Liabilities $262.0K $369.0K $0.00
Total Liabilities $11.49M $12.09M $11.26M
YoY Change 14.59% 7.38% 51.97%
SHAREHOLDERS EQUITY
Retained Earnings -$318.2M -$306.1M -$252.8M
YoY Change 20.71% 21.08%
Common Stock $99.00K $99.00K $88.00K
YoY Change 12.5% 12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.87M $70.07M $116.8M
YoY Change
Total Liabilities & Shareholders Equity $70.35M $82.17M $128.1M
YoY Change -40.33% -35.85% 111.56%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$12.10M -$15.09M -$11.14M
YoY Change 12.18% 35.51% 57.84%
Depreciation, Depletion And Amortization $4.000K $4.000K $7.000K
YoY Change -50.0% -42.86% -30.0%
Cash From Operating Activities -$13.01M -$12.25M -$8.102M
YoY Change 21.44% 51.23% 22.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 97.26M
YoY Change -100.0% -100.0% -25695.26%
NET CHANGE
Cash From Operating Activities -13.01M -12.25M -8.102M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 0.000 97.26M
Net Change In Cash -13.01M -12.25M 89.16M
YoY Change 30.65% -113.74% -1379.2%
FREE CASH FLOW
Cash From Operating Activities -$13.01M -$12.25M -$8.102M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76631172
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15094000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113239092
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78218774
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113239092
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11139000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42494000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29799000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113239092
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78218774
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113239092
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76631172
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
dei Entity Central Index Key
EntityCentralIndexKey
0001509745
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99021376
lptx Operating Lease Additional Liability
OperatingLeaseAdditionalLiability
609000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88318454
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37990
dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike St, Suite B1-1
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-0360
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
99021376
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78308000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114916000
CY2022Q3 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
1256000
CY2021Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
1189000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
374000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
769000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
79938000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
116874000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
767000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
459000
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
142000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
159000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1249000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
293000
CY2022Q3 us-gaap Assets
Assets
82165000
CY2021Q4 us-gaap Assets
Assets
117911000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6276000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4189000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5042000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5366000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
405000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11723000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9987000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
369000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2022Q3 us-gaap Liabilities
Liabilities
12092000
CY2021Q4 us-gaap Liabilities
Liabilities
10024000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99021376
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88318454
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
99000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
88000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
375350000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371638000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
690000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-267000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306066000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263572000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70073000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82165000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117911000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
375000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1125000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12102000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10077000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33931000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24090000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3186000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2438000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8889000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7973000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
15288000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
12515000
us-gaap Operating Expenses
OperatingExpenses
42820000
us-gaap Operating Expenses
OperatingExpenses
32063000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15288000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12140000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42820000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30938000
CY2022Q3 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
360000
CY2021Q3 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
1000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
404000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
4000
CY2022Q3 us-gaap Interest Expense
InterestExpense
11000
CY2021Q3 us-gaap Interest Expense
InterestExpense
9000
us-gaap Interest Expense
InterestExpense
49000
us-gaap Interest Expense
InterestExpense
39000
CY2022Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
652000
CY2021Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1269000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1276000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1584000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-807000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-260000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1305000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-410000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15094000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11139000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42494000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29799000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113239092
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78218774
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113239092
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76631172
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15094000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11139000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
us-gaap Net Income Loss
NetIncomeLoss
-29799000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
596000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
203000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
957000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
333000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14498000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10936000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41537000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29466000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29884000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
40000
CY2021Q3 lptx Stock And Prefunded Warrants Issued During Period Value
StockAndPrefundedWarrantsIssuedDuringPeriodValue
96828000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
203000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1003000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11139000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
116819000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
46651000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
54000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
lptx Stock And Prefunded Warrants Issued During Period Value
StockAndPrefundedWarrantsIssuedDuringPeriodValue
96828000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
333000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2748000
us-gaap Net Income Loss
NetIncomeLoss
-29799000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
116819000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
83318000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
596000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1253000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15094000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70073000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
957000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3723000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70073000
us-gaap Profit Loss
ProfitLoss
-42494000
us-gaap Profit Loss
ProfitLoss
-29799000
us-gaap Depreciation
Depreciation
12000
us-gaap Depreciation
Depreciation
21000
lptx Amortization Of Contract Assets
AmortizationOfContractAssets
101000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
302000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
217000
us-gaap Share Based Compensation
ShareBasedCompensation
3723000
us-gaap Share Based Compensation
ShareBasedCompensation
2748000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1305000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-410000
lptx Fair Value Adjustment Of Restricted Stock Liability
FairValueAdjustmentOfRestrictedStockLiability
-204000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-382000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
87000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
212000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
1576000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-209000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2167000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4873000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1125000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-303000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-229000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
912000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36030000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24441000
lptx Proceeds From Issuance Of Common Stock September2021 Public Offering
ProceedsFromIssuanceOfCommonStockSeptember2021PublicOffering
97222000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
54000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
210000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-210000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
97280000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-368000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-139000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36608000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72700000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52071000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78308000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124771000
lptx Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
394000
lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
609000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78308000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306066000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78308000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2021 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022Q3 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1256000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
CY2022Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
652000
CY2021Q3 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1269000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1276000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1584000
CY2022Q3 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
-1064000
CY2020Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
73000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
-1226000
CY2021 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
111000
CY2021 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
1000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1276000
lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
1064000
lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-145000
CY2022Q3 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1256000
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1249000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
293000
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
75129000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
75129000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
112726000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112726000
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
75129000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
112726000
CY2022Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
lptx Upfront Fees
UpfrontFees
3000000
CY2022Q3 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
270000
CY2021Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
34000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
101000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
0
CY2022Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0
CY2022Q3 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
3022000
CY2021Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2499000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
167000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
181000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1853000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2686000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5042000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5366000
lptx Operating Lease Additional Right Of Use Asset
OperatingLeaseAdditionalRightOfUseAsset
609000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
767000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
116000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
105000
us-gaap Operating Lease Expense
OperatingLeaseExpense
336000
us-gaap Operating Lease Expense
OperatingLeaseExpense
315000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
111000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
452000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
268000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
831000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
57000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
774000
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
49673390
lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8525618
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.48
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3900000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
492915
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.17
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11932703
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6907653
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M20D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11932703
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.10
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8270
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6694
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0306
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0081
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y9M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5493000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M21D
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15094000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11139000
us-gaap Net Income Loss
NetIncomeLoss
-42494000
us-gaap Net Income Loss
NetIncomeLoss
-29799000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15094000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11139000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42494000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29799000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113239092
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78218774
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113239092
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76631172
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
14217716
CY2022Q3 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
14217716
lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
24930483
CY2021Q3 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
24930483
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50973983
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
45353534
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50973983
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
45353534
CY2022Q3 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
3214000

Files In Submission

Name View Source Status
0001104659-22-117613-index-headers.html Edgar Link pending
0001104659-22-117613-index.html Edgar Link pending
0001104659-22-117613.txt Edgar Link pending
0001104659-22-117613-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lptx-20220630.xsd Edgar Link pending
lptx-20220630x10q.htm Edgar Link pending
lptx-20220630xex31d1.htm Edgar Link pending
lptx-20220630xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
lptx-20220630_def.xml Edgar Link unprocessable
lptx-20220630_cal.xml Edgar Link unprocessable
lptx-20220630_pre.xml Edgar Link unprocessable
lptx-20220630x10q_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lptx-20220630_lab.xml Edgar Link unprocessable